Post by Verve Therapeutics

We announced today that Verve has entered into a definitive agreement to be acquired by Eli Lilly and Company. Lilly shares our determination and dedication to transform the treatment paradigm for the millions of patients worldwide living with cardiovascular disease, and we believe Lilly’s global research, clinical, regulatory and commercial capabilities will help accelerate the development of our novel class of single-course gene editing medicines. Please refer to today’s full announcement for key information and cautionary statements: https://lnkd.in/e34ZSXbh